The role of clinically relevant intra-abdominal collections after pancreaticoduodenectomy - Scorecard - MDSpire

The role of clinically relevant intra-abdominal collections after pancreaticoduodenectomy

  • By

  • Pablo Lopez

  • Elizabeth Pando

  • Nuria Ortega-Torrecilla

  • Noelia Puertolas

  • Montse Adell

  • Nair Fernandes

  • Daniel Herms

  • Marta Barros

  • Laia Blanco

  • Joaquim Balsells

  • Ramon Charco

  • December 28, 2023

  • 0 min

Share

Clinical Scorecard: The Impact of Clinically Significant Intra-Abdominal Collections Following Pancreaticoduodenectomy

At a Glance

CategoryDetail
ConditionClinically relevant intra-abdominal collections (CR-IC) after pancreaticoduodenectomy (PD)
Key MechanismsPostoperative fluid collections related to anastomotic leaks, infected hematoma, or abscesses leading to complications such as systemic inflammatory response syndrome (SIRS), sepsis, and severe outcomes including hemorrhage
Target PopulationAdult patients undergoing open pancreaticoduodenectomy for benign or malignant pancreatic disease
Care SettingTertiary referral center surgical and postoperative care

Key Highlights

  • CR-IC incidence after PD ranges between 6% and 11%, often associated with postoperative pancreatic fistula (POPF) and other complications.
  • CR-IC requires interventions such as antibiotics, drainage, or surgery and can lead to severe systemic complications including sepsis and life-threatening hemorrhage.
  • Postoperative serum C-reactive protein (CRP) levels on days 3 and 5 may predict development of CR-IC, though this role remains underexplored.

Guideline-Based Recommendations

Diagnosis

  • Use computed tomography (CT) scans selectively based on clinical suspicion of CR-IC or complications such as persistent SIRS or abnormal clinical course.
  • Define CR-IC as intra-abdominal collections on CT that necessitate clinical intervention including antibiotics, drainage, or surgery.
  • Diagnose infected POPF via microbiological culture.

Management

  • Administer antibiotics, perform percutaneous, endoscopic, or surgical drainage, or other interventions when CR-IC is identified.
  • Use somatostatin analogues selectively in cases of POPF.
  • Maintain intra-abdominal drains based on clinical judgment considering drain output, fluid characteristics, and patient condition.
  • Remove externalized pancreatic duct stents approximately 5–6 weeks postoperatively after confirming absence of pancreatic fistula.

Monitoring & Follow-up

  • Measure serum CRP, complete blood counts, and biochemical tests on postoperative days 3 and 5 or when clinical deterioration occurs.
  • Monitor drain output volume and characteristics to guide drain removal decisions.
  • Observe for signs of systemic inflammatory response syndrome (SIRS), abdominal pain, distension, nausea, or vomiting.

Risks

  • CR-IC is associated with higher rates of severe postoperative complications (Clavien-Dindo ≥ III), including sepsis and hemorrhage.
  • Failure to identify or manage CR-IC can lead to life-threatening outcomes.
  • Elevated postoperative CRP may indicate increased risk for CR-IC.

Patient & Prescribing Data

Adults undergoing open pancreaticoduodenectomy for benign or malignant disease

Somatostatin analogues are not routinely used but reserved for patients who develop POPF; antibiotics and drainage procedures are mainstays of CR-IC management.

Clinical Best Practices

  • Perform pylorus-preserving pancreaticoduodenectomy with duct-to-mucosa pancreatojejunal anastomosis and place two abdominal drains near the anastomosis.
  • Use postoperative CRP levels as a potential predictive marker for CR-IC to guide early intervention.
  • Base drain removal on clinical assessment including drain output, fluid characteristics, and patient recovery status.
  • Employ CT imaging judiciously guided by clinical signs rather than routine scanning.
  • Address underlying causes of CR-IC promptly to prevent progression to severe complications.

References

Original Source(s)

Related Content